Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) is a clinical-stage biotechnology company developing gene circuit medicines engineered to program therapeutic cells with enhanced precision, with an initial focus on oncology and other serious diseases. The company became publicly traded in June 2022 through a business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS), a blank-check company sponsored by Dynamics Special Purpose Holdings LLC, an affiliate of Foresite Capital, which completed its IPO in 2021. Operating within the cell and gene therapy sector, Senti Bio filed an 8-K with the Securities and Exchange Commission on August 20, 2026, representing the company's continued public-reporting obligations. For full filing history, sponsor details, and deal analytics on SNTI and hundreds of other SPAC transactions, sign up for a free SpacDesk account at spacdesk.com.